Success Metrics

Clinical Success Rate
86.6%

Based on 265 completed trials

Completion Rate
87%(265/306)
Active Trials
22(6%)
Results Posted
50%(133 trials)
Terminated
41(11%)

Phase Distribution

Ph early_phase_1
2
1%
Ph phase_3
37
10%
Ph phase_1
101
26%
Ph not_applicable
30
8%
Ph phase_4
30
8%
Ph phase_2
182
48%

Phase Distribution

103

Early Stage

182

Mid Stage

67

Late Stage

Phase Distribution382 total trials
Early Phase 1First-in-human
2(0.5%)
Phase 1Safety & dosage
101(26.4%)
Phase 2Efficacy & side effects
182(47.6%)
Phase 3Large-scale testing
37(9.7%)
Phase 4Post-market surveillance
30(7.9%)
N/ANon-phased studies
30(7.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.6%

265 of 321 finished

Non-Completion Rate

17.4%

56 ended early

Currently Active

22

trials recruiting

Total Trials

383

all time

Status Distribution
Active(27)
Completed(265)
Terminated(56)
Other(35)

Detailed Status

Completed265
Terminated41
unknown35
Withdrawn15
Recruiting13
Active, not recruiting9

Development Timeline

Analytics

Development Status

Total Trials
383
Active
22
Success Rate
86.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.5%)
Phase 1101 (26.4%)
Phase 2182 (47.6%)
Phase 337 (9.7%)
Phase 430 (7.9%)
N/A30 (7.9%)

Trials by Status

enrolling_by_invitation10%
recruiting133%
terminated4111%
completed26569%
not_yet_recruiting41%
unknown359%
withdrawn154%
active_not_recruiting92%

Recent Activity

Clinical Trials (383)

Showing 20 of 383 trialsScroll for more
NCT05600426Phase 3

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active Not Recruiting
NCT06013423Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Recruiting
NCT02416388Phase 2

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting
NCT01624805Phase 2

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Recruiting
NCT03128034Phase 1

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Recruiting
NCT06364319Phase 4

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Not Yet Recruiting
NCT06424639Phase 4

Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA

Withdrawn
NCT00534430Phase 2

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Completed
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT00544115Phase 2

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active Not Recruiting
NCT04195633Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting
NCT03434730Phase 2

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Completed
NCT05573230Phase 1

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Completed
NCT06752694Phase 2

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Active Not Recruiting
NCT03246906Phase 2

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Terminated
NCT07566377Phase 2

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Recruiting
NCT04888741Phase 2

Methods of T Cell Depletion Trial (MoTD)

Recruiting
NCT01231412Phase 3

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Completed
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
383